JAK3 and cancer: Among the recurrently altered and almost invariably clonal epigenetic changes, we found a JAK3 promoter gain of accessibility in 11/24 cancers (Fig. 3d), as well as loss of chromatin accessibility in the CRC tumour suppressor gene CCDC6. This was the case for both the promoter (12/24 cancers) and an associated enhancer region (3/24 cancers); see, for example, case C524 in Supplementary Fig. 5A.